Premium
Efficacy and safety of tofogliflozin in J apanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy ( J‐STEP / INS ): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
Author(s) -
Terauchi Yasuo,
Tamura Masahiro,
Senda Masayuki,
Gunji Ryoji,
Kaku Kohei
Publication year - 2017
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12957
Subject(s) - placebo , medicine , insulin , postprandial , endocrinology , type 2 diabetes , type 2 diabetes mellitus , gastroenterology , diabetes mellitus , clinical endpoint , randomized controlled trial , urology , alternative medicine , pathology
Aims To assess the effects of 16 weeks of tofogliflozin (sodium‐glucose co‐transporter‐2 [ SGLT2 ] inhibitor) treatment vs placebo on glycated haemoglobin ( HbA1c ) levels in Japanese patients with type 2 diabetes mellitus ( T2DM ) inadequately controlled with insulin monotherapy or insulin plus a dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor. Methods The study comprised a 16‐week, multicentre, double‐blind, placebo‐controlled period and a 36‐week extension ( NCT02201004 ). Men and women (aged ≥20 and ≤75 years) with T2DM ( HbA1c ≥7.5% and ≤10.5%) were randomized 2:1 to tofogliflozin 20 mg once/day or placebo. The primary endpoint was change in HbA1c from baseline. Insulin reduction was not permitted during this study. Results A total of 211 patients were randomized (141 tofogliflozin, 70 placebo). Addition of tofogliflozin to insulin therapy was significantly superior to placebo for lowering HbA1c (−0.59 vs +0.48%; P < .0001), fasting plasma glucose (−27.2 vs +5.3 mg/ dL ; P < .0001), postprandial plasma glucose (−65.0 vs +3.2 mg/ dL ; P < 0.0001), serum uric acid (−0.18 vs +0.07 mg/ dL ; P = .0062), body weight (−1.34 vs +0.03 kg; P < .0001) and daily insulin dose (−1.3 vs −0.2 U, P = .0152). Hypoglycaemia occurred in 30.7% of patients receiving tofogliflozin vs 21.4% for placebo. Two patients treated with tofogliflozin each had a genital or urinary tract infection. Conclusions This 16‐week double‐blind study indicated that, in patients with T2DM whose HbA1c levels were poorly controlled with insulin monotherapy or insulin plus a DPP ‐4 inhibitor, addition of tofogliflozin was an effective treatment option with an acceptable safety profile.